Keros Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $18,168 | $367 | $385 | $14,262 |
Gross Profit | -36 | 385 | 13,867 | |
EBITDA | -28,308 | -23,305 | -24,575 | -8,309 |
EBIT | -28,710 | -23,708 | -24,975 | -8,704 |
Net Income | -28,710 | -23,708 | -23,461 | -7,280 |
Net Change In Cash | 18,168 | 367 | 385 | 14,262 |
Free Cash Flow | -20,576 | -3,602 | -27,426 | 3,117 |
Cash | 257,606 | 281,497 | 287,415 | 693,472 |
Basic Shares | 19,800 | 19,629 | 27,198 | 40,623 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $244,061 | $3,550 | $151 | $20,000 |
Gross Profit | 242,552 | 3,550 | 151 | -1,615 |
EBITDA | 93,406 | -185,824 | -152,177 | -104,004 |
EBIT | 91,897 | -187,053 | -152,992 | -104,678 |
Net Income | 87,014 | -187,353 | -152,992 | -104,679 |
Net Change In Cash | 244,061 | 3,550 | 151 | 20,000 |
Cost of Revenue | 49,006 | |||
Free Cash Flow | 105,954 | -162,800 | -126,972 | -71,303 |
Cash | 287,415 | 559,931 | 331,147 | 279,048 |
Basic Shares | 37,859 | 37,438 | 29,447 | 25,241 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.45 |
2026-03-31 | -$1.21 |
2025-12-31 | -$0.86 |
2025-09-30 | -$0.18 |